Page 3 - Danieled Ambrosio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomRegion flamandeNorthern irelandGreat britainClin rheumatolSandra cauwenberghsVan gijselMarieke vermeerschDaniele dambrosioPeuropean league against rheumatismGilead sciences incExchange commissionRheumatology internationalEuropean unionJapanese ministry of healthDanieled ambrosio

Galapagos NV (NASDAQ:GLPG) Q1 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Galapagos Q1 2023 Financial Results Conference Call. [Operator Instructions].

United statesFrance generalDane leonePaulus stoffelsDaniele dambrosioMichele mantoVan gijselBrian balchinPaul stoffelsBart filiusPeter verdultBrian abrahamsRaymond jamesJason gerberryMorgan stanleyCall transcript may

Study for painful, highly inflammatory condition initiated by Galapagos

Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).

Nordrhein westfalenDaniele dambrosioXenofon baraliakosUniversity bochumAnkylosing spondylitis disease activity scoreRuhr university bochumDanieled ambrosioPreclinical researchClinical developmentAtient centricityLinical evolutionPis active pharmaceutical ingredientsHasei iiPhase iii ivRheumatoid arthritisPsoriatic arthritis

Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA

Nordrhein westfalenRegion flamandeUnited kingdomNorthern irelandGreat britainVan gijselMarieke vermeerschDaniele dambrosioXenofon baraliakosElisa chenaillerSandra cauwenberghsEuropean unionJapanese ministry of healthUniversity bochumExchange commissionEuropean medicines agency

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Investegate announcements from Galapagos NV, Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Nordrhein westfalenUnited kingdomRegion flamandeNorthern irelandGreat britainVan gijselDaniele dambrosioMarieke vermeerschXenofon baraliakosElisa chenaillerSandra cauwenberghsPercentage of participants achieving spondyloarthritis international societyEuropean unionJapanese ministry of healthGilead sciences incUniversity bochum